Market Blog » The Arora Report Stock Market News

BUFFETT SELLS STOCKS – HERE IS WHAT PRUDENT INVESTORS SHOULD DO NOW, OPEC+ CHANGES STANCE

November 3, 2025

By Nigam Arora To gain an edge, this is what you need to know today. Buffett Sells Stocks Please click here for a chart of Warren Buffett’s company Berkshire Hathaway stock (BRK.B). Note the following: The Morning Capsule is about the big picture, not an individual stock. The chart of BRK.B is being used to illustrate the point. The chart shows BRK.B stock has pulled back from highs earlier this year. The chart shows BRK.B is in zone 2 (support). RSI on the chart shows BRK.B stock is neither overbought nor oversold. Warren Buffett is the most successful investor of our

WEEKLY STOCK MARKET DIGEST: WHAT PRUDENT INVESTORS NEED TO KNOW NOW

November 1, 2025

By Nigam Arora Weekly Digest from The Arora Report is popular among serious investors and money managers because they have found studying insights from the prior week gives them an edge over the coming weeks. Here is the day by day rundown from the morning capsules made available every morning before the market open in the Real Time Feeds to the paying subscribers of The Arora Report. Please scroll down for the section ‘Protection Bands and What To Do Now.’ CRITICAL POWELL SPEECH AMAZON STOCK BREAKS OUT ON INSATIABLE AI DEMAND, APPLE BUOYED ON RUSH TO UPDATE IPHONES, SENTIMENT

245% GAIN ON CANCER DETECTION COMPANY GH – ANOTHER 1000% GAIN POTENTIAL – BUYOUT TARGET

October 31, 2025

By Nigam Arora 245% Gain Guardant Health (GH) is long from $26.34. It is trading at $91.02 as of this writing, representing a 245% gain. Buyout Target GH is a buyout target. Cancer Screening Guardant Health is using advanced blood-based liquid biopsy tests and large clinical data sets to transform how cancer is detected, monitored, and treated. The company’s core business includes its flagship Guardant360 liquid biopsy panel, Guardant Reveal for monitoring minimal residual disease, and early blood based cancer screening test Shield. Potential Headwinds Guardant Health is still working toward sustained profitability. It also faces competition from other diagnostics players

POWELL THROWS COLD WATER ON MOMO GURUS’ NARRATIVE

October 30, 2025

By Nigam Arora Editor’s note: This post was published yesterday in The Arora Report paid feeds as an Afternoon Capsule. To gain an edge, this is what you need to know now. December Not A Done Deal Please click here for a chart of S&P 500 ETF (SPY) which represents the benchmark stock market index S&P 500 (SPX). Note the following: The chart shows when the FOMC interest rate decision was announced. As expected, the Fed cut interest rates by 25 bps. The chart shows the initial negative stock market reaction to Fed Chair Powell’s press conference as Fed Chair Powell

NVIDIA SHOCKS STOCK MARKET AND SHARES SOAR AS TRUMP FUELS HOPES OF CHINA BLACKWELL SALES, BUYING AHEAD OF FED

October 29, 2025

By Nigam Arora To gain an edge, this is what you need to know today. Two Nvidia Shockers Please click here for a chart of Nvidia stock (NVDA). Note the following: The Morning Capsule is about the big picture, not an individual stock. The chart of NVDA stock is being used to illustrate the point. The chart shows a big move up yesterday on a revenue shocker and flurry of deals from Nvidia. The chart shows another up move in NVDA stock driven by President Trump. Yesterday, revenue projections from Nvidia were a shocker. Here are the key points: Nvidia has

EPI, SMIN, GLIN: IMPLICATIONS FOR INDIA OF RUSSIAN OIL SANCTIONS

October 28, 2025

By Nigam Arora Editor’s note: This signal was published on October 23, 2025, in ZYX Emerging Alert for paid members. Russian Oil Please start out by reading the Morning Capsule published on October 23rd. Here are the key points: India imports 38% of Russia’s oil. India is reportedly getting a 15% – 25% discount over the market price. If India is not able to import oil from Russia, this is negative for India. If India stops importing oil from Russia, the 50% tariffs will likely be lifted. This is positive for India. Very Long Term For the very long term, India

DON’T MISS THE NEXT BIG BUYOUT — THE ARORA REPORT CELEBRATES 215 BUYOUTS

October 27, 2025

By Nigam Arora 215 Buyouts — A New Record of Success for Arora Members Avidity Biosciences (RNA) has received a buyout offer from Novartis (NVS) for approximately $12B. RNA is the 215th Arora Portfolio company to be bought out. This milestone demonstrates the strength of The Arora Report’s approach. Neuromuscular Diseases Avidity Biosciences is developing RNA-targeted therapies using its antibody-oligonucleotide conjugate platform to address serious neuromuscular diseases, including Duchenne muscular dystrophy, myotonic dystrophy type 1, and facioscapulohumeral muscular dystrophy. Buyout Details RNA is long from $42. The buyout offer is for $72 per share in cash, roughly a 46% premium to

WEEKLY STOCK MARKET DIGEST: WHAT PRUDENT INVESTORS NEED TO KNOW NOW

October 25, 2025

By Nigam Arora Weekly Digest from The Arora Report is popular among serious investors and money managers because they have found studying insights from the prior week gives them an edge over the coming weeks. Here is the day by day rundown from the morning capsules made available every morning before the market open in the Real Time Feeds to the paying subscribers of The Arora Report. Please scroll down for the section ‘Protection Bands and What To Do Now.’ DEPLOY CASH – COOLER CPI PROVIDES FUEL FOR STOCK MARKET TO MOVE TO THE MAGNET BUT RISKS REMAIN Oct